Welcome to our dedicated page for MESOBLAST SEC filings (Ticker: MEOBF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MESOBLAST's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MESOBLAST's regulatory disclosures and financial reporting.
Mesoblast Limited furnished a Form 6-K that forwards several Australian Securities Exchange appendices on new equity issues and changes in securities, including a detailed change of director’s interest notice for Gregory George.
The notice shows an increase in his indirect holdings after on-market purchases by related holders. These trades added 70,000 American Depositary Shares (ADS), with each ADS representing 10 ordinary shares, and 7,210,962 ordinary shares. The filing states total cash consideration of US$11,429,969.84 for the ADS and ordinary shares purchased. Following the transactions, his indirect interests rose to 12,855,154 ordinary shares, 14,485,410 ADS, and 6,830,602 warrants to acquire ordinary shares, while his direct positions were unchanged.
Mesoblast Limited reported that it has acquired an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform designed to enhance its mesenchymal stromal cell (MSC) therapies. The CAR constructs are intended to improve targeted homing of MSCs to inflamed tissues, aiming to increase potency in inflammatory and autoimmune diseases.
The intellectual property, originally developed at Mayo Clinic and published in Nature Biomedical Engineering, may support new or stronger indications such as ulcerative colitis, Crohn's disease, Lupus Nephritis and other B cell–driven conditions. Mesoblast obtained the rights via acquiring a startup formed to advance the CAR-MSC technology, paying with ASX ordinary shares, and Mayo Clinic will provide in-kind support including GMP manufacturing activities.
Mesoblast Ltd director and ten percent owner George Gregory reported a series of indirect open-market purchases of Ordinary Shares. Between April 4 and April 10, related accounts for Grant George and James George, each granting power of attorney to Dr. George, bought a combined 7,910,962 Ordinary Shares at prices between $1.41 and $1.48 per share. The filing shows indirect holdings in these accounts increasing to as many as 13,586,890 Ordinary Shares following the transactions. A footnote explains that these Ordinary Shares are represented by American Depositary Shares, with each ADS reflecting a beneficial interest in 10 Ordinary Shares, and that reported prices are already adjusted to the per‑Ordinary‑Share level.
Mesoblast Limited used its R&D Day to highlight rapid commercial progress with Ryoncil and a late‑stage pipeline targeting multi‑billion‑dollar inflammatory indications. Ryoncil net revenue is approaching US$100 million since its U.S. launch last year, with Q3 FY26 gross revenue of US$35 million and net revenue of US$30 million.
The company reported H1 FY26 Ryoncil gross profit of US$44 million against US$7 million in direct selling costs, and a cash balance of US$130 million at December 31 2025, supported by a new US$125 million term loan. Management targets FY26 net revenue of US$110–120 million and aims to double Ryoncil revenue.
Mesoblast is advancing Phase 3 programs for chronic low back pain and inflammatory heart failure, each with stated total addressable markets above US$10 billion, plus label extensions for Ryoncil in adult SR‑aGvHD and Duchenne muscular dystrophy. Next‑generation CAR‑ and oncolytic virus‑engineered MSC platforms and manufacturing upgrades are intended to support long‑term growth.
Mesoblast Ltd director William Murray Burns filed an initial Form 3 showing his beneficial holdings in the company. The filing lists several option awards over Ordinary Shares with exercise prices ranging from $0.36 to $1.81 per share and expirations between 2026 and 2031. It also reports direct ownership of 226,250 Ordinary Shares as of the reporting date. These entries reflect existing positions rather than new purchases or sales.
Mesoblast Ltd CEO and Managing Director Silviu Itescu reported his existing ownership of Ordinary Shares and stock options. He directly holds 67,756,838 Ordinary Shares and has additional indirect holdings through entities associated with him. He also holds multiple option awards over Ordinary Shares with exercise prices from 0.3500 to 2.4600 per share, expiring between 2026 and 2032.
Mesoblast Ltd director George Gregory filed an initial ownership report listing his existing holdings in the company. The filing shows direct and indirect positions in ordinary shares, American Depositary Shares, warrants, and stock options with various exercise prices and expirations. A footnote explains that each ADS represents a beneficial interest in 10 ordinary shares.
Mesoblast Limited furnished a Form 6-K summarizing Australian Securities Exchange disclosures about director equity awards and other unquoted securities. The filing attaches Appendix 3Y notices showing option grants, with no cash consideration, to multiple directors following shareholder approval at the 2025 annual general meeting.
Chief Executive Officer Dr Silviu Itescu received 2,025,600 new options, increasing his option holdings to 18,475,158 while his 78,958,928 ordinary shares were unchanged. Director Dr Eric Rose received 820,000 options, bringing his total to 6,413,451 options with 6,749,274 ordinary shares unchanged. Director Gregory George received 200,000 options to acquire ordinary shares under the employee share option plan. Director Lyn Cobley received 200,000 options, adding to her existing direct and indirect shareholdings. The 6-K also forwards an Appendix 3G notice on unquoted equity securities.
Mesoblast Ltd director Philip R. Krause has filed an initial ownership report showing his equity position in the company. He directly holds 287,500 Ordinary Shares, which are represented by American Depositary Shares. In addition, he holds multiple option awards over Ordinary Shares with exercise prices between $0.32 and $0.99 per share and expirations ranging from 2029 to 2031. Footnotes indicate that certain options were granted in 2023 and 2024 and are scheduled to vest between October 24, 2026 and August 27, 2027, aligning his compensation with the company’s long-term performance.
Mesoblast Ltd director Philip James Facchina filed an initial Form 3, disclosing his existing equity-linked interests in the company. He reports multiple options (rights to buy Ordinary Shares) with exercise prices of $2.26, $0.36, and $0.97 per share and expirations between 2028 and 2031. He also reports warrants and Ordinary Shares held indirectly through HNP, LLC, a company in which he is a member. The footnotes state that the Ordinary Shares are represented by American Depositary Shares.